Jones James 4

What Happened

• James Jones, a director of Cumberland Pharmaceuticals, was granted 1,800 shares as an award/acquisition on March 18, 2026.
• The shares were recorded at $2.80 each, for a total value of $5,040. This is an acquisition via award (code A), not an open-market purchase or sale.

Key Details

• Transaction date and price: March 18, 2026 — 1,800 shares at $2.80 per share.
• Total value of grant: $5,040.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes/plan: No additional footnotes or details (e.g., 10b5-1 plan, tax withholding) were provided in the supplied data.
• Filing timeliness: Form 4 was filed on March 20, 2026; this appears to be a timely filing (no late-filing flag indicated).

Context

• An "A" code award typically reflects a grant of shares under a company equity or compensation plan (e.g., restricted stock or similar). Such awards are compensation-related and do not necessarily signal the director buying shares on the open market.
• The economic size of this grant ($5,040) is modest; retail investors often view purchases (open-market buys) as more direct indicators of insider conviction, while awards are part of routine compensation.